Skip to main content
Porton Pharma Solutions Ltd. logo

Porton Pharma Solutions Ltd. — Investor Relations & Filings

Ticker · 300363 ISIN · CNE100001S57 LEI · 300300IQTJFHA0YRXE68 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,163 across all filing types
Latest filing 2025-04-24 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 300363

About Porton Pharma Solutions Ltd.

https://www.porton.cn

Porton Pharma Solutions Ltd. is a global contract development and manufacturing organization (CDMO) providing end-to-end solutions for the pharmaceutical and biotechnology sectors. The company specializes in the development and manufacturing of small molecule APIs, intermediates, and drug products, while expanding its capabilities into biologics and cell and gene therapies. Its service portfolio encompasses process research and development, analytical services, pilot-scale production, and large-scale commercial manufacturing. Porton operates a network of R&D centers and manufacturing facilities designed to meet international regulatory standards, including those of the FDA and EMA. By leveraging an integrated technology platform, the company supports clients throughout the entire drug lifecycle, from preclinical development to commercialization, focusing on operational excellence and supply chain security.

Recent filings

Filing Released Lang Actions
2025年一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "2025年第一季度报告" which translates to "2025 First Quarter Report". It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and management commentary on financial performance for the first quarter of 2025. The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year clearly indicates this is an Interim / Quarterly Report. The document length is substantial (15,000 characters), and it contains actual financial data, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2025-04-24 Chinese
监事会关于作废部分2022年限制性股票激励计划已授予但尚未归属的限制性股票的核查意见
Board/Management Information Classification · 95% confidence The document is a supervisory board opinion regarding the cancellation of part of the 2022 restricted stock incentive plan that has been granted but not yet vested. It references compliance with company law, securities law, and regulatory guidelines, and provides an official opinion on the legality and fairness of the cancellation. The content focuses on governance and compliance related to stock incentives rather than financial results, capital changes, or voting outcomes. It is not a full report, earnings release, or announcement of voting results. The document is a formal governance-related statement from the supervisory board about stock incentive plan administration, fitting best under Board/Management Information (MANG). The document length is short but contains substantive governance content, not just an announcement or certification, so it is not RNS or RPA.
2025-04-24 Chinese
第五届董事会第三十二次临时会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 32nd extraordinary meeting of the 5th Board of Directors of Chongqing Boteng Pharmaceutical Technology Co., Ltd. It includes details about the meeting date, voting results, and specific agenda items such as approval of the 2025 Q1 report, audit committee work summary, cancellation of restricted stock incentives, and adoption of a market value management system. The document references other announcements for detailed reports but itself is a board meeting resolution announcement. This fits the category of Board/Management Information (MANG), as it concerns board decisions and management matters rather than the full report or financial data. The document length is short and it is not the report itself but a meeting resolution announcement.
2025-04-24 Chinese
第五届监事会第二十三次临时会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Chongqing Boteng Pharmaceutical Technology Co., Ltd. It details the approval of the 2025 first quarter report and the cancellation of certain restricted stock awards. The document references the actual 2025 first quarter report and a separate announcement about the stock incentive plan cancellation, both published elsewhere. The text itself is a formal meeting resolution and does not contain the full quarterly report or detailed financial data. It is a regulatory announcement about board decisions rather than the report itself. Given the short length (1103 characters) and the nature of the content, this fits best as a Regulatory Filing (RNS) rather than an Interim/Quarterly Report (IR) or other report types.
2025-04-24 Chinese
关于举行2024年度网上业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about holding a 2024 annual performance explanation meeting (业绩说明会) scheduled for April 15, 2025. It references that the 2024 annual report has already been disclosed on March 29, 2025. The document invites investors to participate in the meeting and submit questions in advance. The document length is short (1027 characters) and it does not contain any financial data or detailed report content itself. It is clearly an announcement about an investor presentation event related to the annual report, not the report itself or a transcript. Therefore, the document fits best as an Investor Presentation (IP) announcement or related notice. However, since it is announcing the holding of a performance explanation meeting (which is a form of investor presentation), the best classification is Investor Presentation (IP).
2025-04-09 Chinese
关于召开2024年年度股东会的通知
AGM Information Classification · 100% confidence The document is a detailed notice about the convening of the 2024 Annual General Meeting (AGM) of Chongqing Porton Pharmaceutical Technology Co., Ltd. It includes information about the meeting date, voting procedures, proposals to be voted on, and instructions for shareholders. It does not contain financial statements or detailed financial analysis but rather the agenda and procedural details for the AGM. This matches the description of 'AGM Information' which includes presentations and materials shared during the AGM. The document is not an announcement of voting results, nor is it a full annual report or any other financial report. Therefore, the correct classification is AGM Information (AGM-R).
2025-04-07 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.